Animal models of attention-deficit hyperactivity disorder

被引:164
作者
Davids, E
Zhang, KH
Tarazi, FI
Baldessarini, RJ
机构
[1] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA
[2] Harvard Univ, Sch Med, Neurosci Program, Belmont, MA 02178 USA
[3] Massachusetts Gen Hosp, Mailman Res Ctr, McLean Div, Belmont, MA 02178 USA
[4] Univ Essen Gesamthsch, Dept Psychiat & Psychotherapy, Essen, Germany
基金
美国国家卫生研究院;
关键词
attention deficit-hyperactivity disorder; behavior; dopamine; hyperactivity; norepinephrine; serotonin; stimulants;
D O I
10.1016/S0165-0173(02)00274-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Attention-deficit hyperactivity disorder (ADHD) involves clinically heterogeneous dysfunctions of sustained attention, with behavioral overactivity and impulsivity, of juvenile onset. Experimental models, in addition to mimicking syndromal features, should resemble the clinical condition in pathophysiology, and predict potential new treatments. One of the most extensively evaluated animal models of ADHD is the spontaneously hypertensive rat. Other models include additional genetic variants (dopamine transporter gene knock-out mouse, coloboma mouse, Naples hyperexcitable rat, acallosal mouse, hyposexual rat, and population-extreme rodents), neonatal lesioning of dopamine neurons with 6-hydroxydopamine, and exposure to other neurotoxins or hippocampal irradiation. None is fully comparable to clinical ADHD. The pathophysiology involved varies, including both deficient and excessive dopaminergic functioning, and probable involvement of other monoamine neurotransmitters. Improved models as well as further testing of their ability to predict treatment responses are required. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:1 / 21
页数:21
相关论文
共 314 条
  • [1] Design, synthesis, and structure-activity relationships of acetylene-based histamine H3 receptor antagonists
    Ali, SM
    Tedford, CE
    Gregory, R
    Handley, MK
    Yates, SL
    Hirth, WW
    Phillips, JG
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (05) : 903 - 909
  • [3] HIPPOCAMPUS AND BEHAVIORAL MATURATION
    ALTMAN, J
    BRUNNER, RL
    BAYER, SA
    [J]. BEHAVIORAL BIOLOGY, 1973, 8 (05): : 557 - 596
  • [4] Validity of the age-of-onset criterion for ADHD: A report from the DSM-IV field trials
    Applegate, B
    Lahey, BB
    Hart, EL
    Biederman, J
    Hynd, GW
    Barkley, RA
    Ollendick, T
    Frick, PJ
    Greenhill, L
    McBurnett, K
    Newcorn, JH
    Kerdyk, L
    Garfinkel, B
    Waldman, I
    Shaffer, D
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 1997, 36 (09) : 1211 - 1221
  • [5] NEONATAL 6-HYDROXYDOPAMINE-INDUCED DOPAMINE DEPLETIONS - MOTOR-ACTIVITY AND PERFORMANCE IN MAZE-LEARNING
    ARCHER, T
    DANYSZ, W
    FREDRIKSSON, A
    JONSSON, G
    LUTHMAN, J
    SUNDSTROM, E
    TEILING, A
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1988, 31 (02) : 357 - 364
  • [6] Sex differences in ADHD: Conference summary
    Arnold, LE
    [J]. JOURNAL OF ABNORMAL CHILD PSYCHOLOGY, 1996, 24 (05) : 555 - 569
  • [7] Arnsten A F, 2001, Adv Neurol, V85, P333
  • [8] Genetics of childhood disorders: XVIII. ADHD, Part 2: Norepinephrine has a critical modulatory influence on prefrontal cortical function
    Arnsten, AFT
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2000, 39 (09) : 1201 - 1203
  • [9] ARNSTEN AFT, 1988, J NEUROSCI, V8, P4287
  • [10] Catecholamine regulation of the prefrontal cortex
    Arnsten, AFT
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 1997, 11 (02) : 151 - 162